Spotlight Innovation Subsidiary Celtic Biotech Iowa Receives Approval to Commence Phase I Part 2 Clinical Trial of Crotoxin The French National Agency for the Safety of Medicines and Health Products Has Approved Additional Testing of Cancer Drug Candidate PR Newswire WEST DES MOINES, Iowa, Nov. 10, 2016 WEST DES MOINES, Iowa , Nov. 10, 2016 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) announced today that its subsidiary Celtic Biotech Iowa has received approval from the French...